bims-netuvo Biomed News
on Nerves in tumours of visceral organs
Issue of 2025–01–05
four papers selected by
Maksym V. Kopanitsa, Charles River Laboratories



  1. Cancer Lett. 2024 Dec 28. pii: S0304-3835(24)00828-0. [Epub ahead of print]611 217433
      The nervous system governs both ontogeny and oncology. Foundational discoveries have clarified the direct communication of neurotransmitters with tumors and indirect interactions through neural effects on the immune system and the tumor microenvironment. Meantime, the nervous system is susceptible to cancer and its treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is the most common side effects that significantly reduce the efficacy of anti-cancer treatment and patients' quality of life by leading to dose reduction or early cessation of chemotherapy. However, there are no effective strategies to reverse or treat CIPN. A better understanding of the mechanisms is expected to enable the development of the next generation of therapies. Here, we summarize the recent important studies on clinical manifestations, risk factors, prediction, pathogenesis, prevention, and treatment of CIPN. We also provide perspectives and insights regarding the rationales of bidirectional interactions between cancer and the nervous system.
    Keywords:  Adverse effect; Antineoplastic agents; Chemotherapy-induced peripheral neuropathy; Nervous system complications; Neurotoxicity; Symptom management
    DOI:  https://doi.org/10.1016/j.canlet.2024.217433
  2. Cureus. 2024 Nov;16(11): e74589
      Schwannomas are rare, benign tumours arising from Schwann cells, with oesophageal cases representing a small fraction. Their variety of symptoms and nonspecific imaging features often make preoperative diagnosis challenging, frequently requiring immunohistochemical staining for confirmation. We describe the case of a 62-year-old woman with progressive dysphagia, found to have a subepithelial mass at the gastroesophageal junction (GOJ). Imaging and endoscopic ultrasound-guided biopsy confirmed an oesophageal schwannoma. The patient underwent robotic-assisted thoracoscopic excision, which allowed for precise tumour removal while avoiding a more extensive oesophagectomy. Intraoperatively, two distinct lobular tumours were identified and successfully excised without compromising the oesophageal mucosa. Postoperatively, the patient recovered well with resolution of symptoms and no evidence of residual tumour on follow-up imaging. This case highlights the potential of robotic-assisted approaches for treating oesophageal schwannomas, which can offer advantages in complex resections by improving surgical precision and reducing morbidity. Despite promising outcomes, robotic-assisted enucleation of oesophageal schwannomas remains rare, with few cases documented. This case supports robotic resection of oesophageal schwannomas as a feasible option in specialized settings, but further studies are needed to establish its role and develop recommendations.
    Keywords:  esophageal tumor; gastro-esophageal surgery; minimally invasive surgical procedures; robotic surgical management; robotic surgical procedures; robotic thorascopic surgery; schwannoma; surgical enucleation; upper gi surgery; upper gi tumor
    DOI:  https://doi.org/10.7759/cureus.74589
  3. J Neurooncol. 2025 Jan 02.
       PURPOSE: Availability data are scarce and primarily retrospective in patients with brain metastasis (BM) from gastrointestinal (GI) cancers. The objective of this cohort was to determine prognostic factors for survival outcomes in patients with BM from GI cancers.
    METHODS: METACER is a national multicentric prospective cohort study which included patients with BM diagnosis during a histologically proven digestive cancer follow-up between 2010 and 2014. The primary endpoint was overall survival (OS). The secondary endpoints were Progression-Free survival (PFS), prognostic factors, and BM-free survival as time from disease diagnosis to BM diagnosis.
    RESULTS: METACER included 130 patients, with colorectal cancer (CRC) (N = 105) and eso-gastric (N = 25) cancer (EGC). The median OS was 6.6 months: 7.1 months (95%CI: 4.7-9.7) in CRC patients and 5.2 months, (95%CI: 1.9-7.6) in EG patients (p = 0.827). In multivariate analysis, cerebral BM location (versus cerebellar), BM surgery, performance status (0-1 versus 2), and a unique BM were significantly associated with prolonged OS. BM-free survival were 30.8 months (95%CI:25.2-36.9) in CRC patients and 7.8 months (95%CI:3.8-13.6) in EGC patients (p < 0.001). In synchronous metastatic disease, BM-free survival were 18.6 months (95%CI:13.1-25.2) in CRC patients and 3.7 months (95%CI:0.03-7.8) in EGC patients (p < 0.001).
    CONCLUSION: BM in GI cancers are of poor prognosis. BM surgery should be considered in case of unique brain lesion. In metastatic settings, EGC patients have shorter BM-free survival than CRC patients.
    Keywords:  Brain metastases; Colorectal cancer; Esophageal cancer; Gastric cancer; Metastasis
    DOI:  https://doi.org/10.1007/s11060-024-04905-x
  4. Front Oncol. 2024 ;14 1447508
      The advent and success of new drugs for treating HER2-positive metastatic breast cancer has led to a constant improvement in disease and progression-free survival as well as overall survival. Despite these advantages, the overall survival and quality of life of patients with HER2-positive breast cancer brain metastases are significantly worse than the ones of patients with HER2-positive breast cancer metastases outside the brain. For this reason, prevention and treatment of brain metastasis remain a major clinical challenge and the keys to further improving the clinical and survival outcomes of HER2-positive breast cancer patients. This review discusses the etiopathogenesis of brain metastasis, the currently available treatments, and the future perspective on new treatment strategies and diagnostic tools.
    Keywords:  HER2-positive breast cancer; TKIs; antibody-drug-conjugated; brain metastases; liquid biopsy
    DOI:  https://doi.org/10.3389/fonc.2024.1447508